News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,459 Results
Type
Article (41626)
Company Profile (267)
Press Release (687550)
Multimedia
Podcasts (100)
Webinars (20)
Section
Business (205015)
Career Advice (2033)
Deals (35615)
Drug Delivery (130)
Drug Development (81642)
Employer Resources (174)
FDA (16516)
Job Trends (14989)
News (347102)
Policy (32812)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2595)
Accelerated approval (46)
Adcomms (26)
Allergies (169)
Alliances (49634)
ALS (204)
Alzheimer's disease (1824)
Antibody-drug conjugate (ADC) (429)
Approvals (16874)
Artificial intelligence (634)
Autoimmune disease (258)
Automation (52)
Bankruptcy (362)
Best Places to Work (11642)
BIOSECURE Act (20)
Biosimilars (220)
Biotechnology (177)
Bladder cancer (184)
Brain cancer (70)
Breast cancer (724)
Cancer (5662)
Cardiovascular disease (456)
Career advice (1725)
Career pathing (41)
CAR-T (317)
CDC (54)
Celiac Disease (3)
Cell therapy (848)
Cervical cancer (46)
Clinical research (70658)
Collaboration (2014)
Company closure (5)
Compensation (1332)
Complete response letters (80)
COVID-19 (2737)
CRISPR (104)
C-suite (1068)
Cystic fibrosis (150)
Data (7536)
Decentralized trials (3)
Denatured (27)
Depression (162)
Dermatology (76)
Diabetes (575)
Diagnostics (6894)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (310)
Drug pricing (201)
Drug shortages (32)
Duchenne muscular dystrophy (276)
Earnings (91493)
Editorial (64)
Employer branding (22)
Employer resources (153)
Events (119101)
Executive appointments (1063)
FDA (20134)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1679)
Gene editing (226)
Generative AI (54)
Gene therapy (685)
GLP-1 (1041)
Government (4730)
Grass and pollen (6)
Guidances (403)
Healthcare (18983)
HIV (77)
Huntington's disease (55)
IgA nephropathy (93)
Immunology and inflammation (286)
Immuno-oncology (86)
Indications (176)
Infectious disease (3071)
Inflammatory bowel disease (205)
Inflation Reduction Act (15)
Influenza (135)
Intellectual property (284)
Interviews (318)
IPO (16667)
IRA (50)
Job creations (3654)
Job search strategy (1433)
JPM (60)
Kidney cancer (18)
Labor market (96)
Layoffs (562)
Leadership (38)
Legal (7973)
Liver cancer (99)
Longevity (32)
Lung cancer (753)
Lymphoma (421)
Machine learning (58)
Management (59)
Manufacturing (994)
MASH (179)
Medical device (13903)
Medtech (14001)
Mergers & acquisitions (20163)
Metabolic disorders (1464)
mRNA (196)
Multiple sclerosis (183)
NASH (17)
Neurodegenerative disease (413)
Neuropsychiatric disorders (106)
Neuroscience (3307)
Neurotech (1)
NextGen: Class of 2026 (6535)
Non-profit (4532)
Now hiring (76)
Obesity (687)
Opinion (292)
Ovarian cancer (208)
Pain (247)
Pancreatic cancer (288)
Parkinson's disease (351)
Partnered (33)
Patents (582)
Patient recruitment (643)
Peanut (61)
People (59517)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22015)
Phase 2 (31121)
Phase 3 (23180)
Pipeline (7921)
Policy (312)
Postmarket research (2573)
Preclinical (9368)
Press Release (64)
Prostate cancer (290)
Psychedelics (53)
Radiopharmaceuticals (317)
Rare diseases (1041)
Real estate (5972)
Recruiting (71)
Regulatory (25304)
Reports (55)
Research institute (2414)
Resumes & cover letters (353)
Rett syndrome (36)
RNA editing (20)
RSV (88)
Schizophrenia (177)
Series A (281)
Series B (208)
Service/supplier (11)
Sickle cell disease (109)
Special edition (26)
Spinal muscular atrophy (173)
Sponsored (47)
Startups (3647)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (71)
Vaccines (1081)
Venture capital (103)
Weight loss (441)
Women's health (120)
Worklife (20)
Date
Today (112)
Last 7 days (759)
Last 30 days (2849)
Last 365 days (30220)
2026 (10606)
2025 (30207)
2024 (35241)
2023 (40095)
2022 (51219)
2021 (55749)
2020 (54110)
2019 (46575)
2018 (35049)
2017 (32166)
2016 (31549)
2015 (37587)
2014 (31338)
2013 (26356)
2012 (28583)
2011 (29273)
2010 (27334)
Location
Africa (750)
Alabama (91)
Alaska (7)
Arizona (342)
Arkansas (14)
Asia (39654)
Australia (6501)
California (12814)
Canada (3668)
China (1299)
Colorado (547)
Connecticut (554)
Delaware (390)
Europe (85726)
Florida (1923)
Georgia (411)
Hawaii (3)
Idaho (62)
Illinois (1026)
India (88)
Indiana (585)
Iowa (23)
Japan (514)
Kansas (129)
Kentucky (50)
Louisiana (39)
Maine (75)
Maryland (1541)
Massachusetts (9125)
Michigan (354)
Minnesota (695)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (138)
New Hampshire (84)
New Jersey (3392)
New Mexico (28)
New York (3366)
North Carolina (1626)
North Dakota (8)
Northern California (6391)
Ohio (380)
Oklahoma (23)
Oregon (41)
Pennsylvania (2581)
Puerto Rico (28)
Rhode Island (50)
South America (1120)
South Carolina (85)
South Dakota (2)
Southern California (5043)
Tennessee (206)
Texas (2026)
United States (45278)
Utah (382)
Vermont (1)
Virginia (306)
Washington D.C. (80)
Washington State (1028)
West Virginia (4)
Wisconsin (122)
Wyoming (2)
729,459 Results for "biogen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer’s market as patients end their 18-month course of Lilly’s product.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Earnings
With growth curve trending up, Biogen looks to early-stage assets for ‘next generation’
Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the pressure and cleared the way for some early-stage bets, CEO Chris Viehbacher said Wednesday.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials.
March 31, 2026
·
4 min read
·
Annalee Armstrong
Earnings
Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline
With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.
February 6, 2026
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
Immunology and Inflammation
Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline
William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunology and inflammation pipeline.
March 30, 2026
·
4 min read
·
Heather McKenzie
Press Releases
BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
March 12, 2026
·
9 min read
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.
November 24, 2025
·
3 min read
·
Heather McKenzie
Neurodegenerative disease
JPM26: With Leqembi Launched, Biogen Looks To Expand Alzheimer’s Presence
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with Eli Lilly and its Kisunla offering—is focused on a near-term FDA decision for a subcutaneous induction dose of Leqembi, a presymptomatic readout in 2028 and a clutch of next-generation candidates.
January 14, 2026
·
5 min read
·
Heather McKenzie
Press Releases
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
April 20, 2026
·
14 min read
1 of 72,946
Next
